UBX - Unity Biotech perks up on positive data from early-stage trial for eye disease

Shidlovski/iStock via Getty Images UNITY Biotechnology (UBX) has added ~13.0% in the pre-market after the company announced promising early-stage data for UBX1325 in patients with diabetic macular edema ((DME)) or wet age-related macular degeneration ((wet AMD)). The phase 1 open-label study included 12 patients with advanced DME or wet AMD who were no longer expected to benefit from anti-VEGF therapy. UBX1325, a small molecule inhibitor of Bcl-xL “was well tolerated with no treatment-related adverse events or dose-limiting toxicities,” the company said, adding that there were only two nonserious, nondrug-related adverse events. Following a single injection of UBX1325, most of the patients in the trial have seen rapid improvements in best-corrected visual acuity ((BCVA)), central subfield thickness ((CST)), and sub- and intra-retinal fluid (SRF, IRF), which are considered as key measures of disease progression. According to data, there are dose-dependent improvements in BCVA and CST. “We are very excited by the initial efficacy we see

For further details see:

Unity Biotech perks up on positive data from early-stage trial for eye disease